Abstract: A dietary supplement composition, used for treating hypertension in human subjects, includes nicotinamide mononucleotide (NMN) in the amount about 300-600 mg. In another embodiment, the dietary supplement composition includes NMN in the amount about 300-600 mg and trans-resveratrol in the amount about 250-500 mg. A method of treating a hypertension disorder includes the steps of identifying a subject in need of treatment for hypertension, and administering the dietary supplement composition to the subject, in which the dietary supplement composition includes NMN in the amount about 300-600 mg. In another embodiment of method of treating a hypertension disorder includes the steps of identifying a subject in need of treatment of the hypertension, and administering the dietary supplement composition to the subject, in which the dietary supplement composition includes NMN in the amount about 300-600 mg and trans-resveratrol in the amount about 250-500 mg.

Abstract: A dietary supplement composition, which may be used for treating neurological and developmental disorders in human subjects, includes trans-resveratrol, ginkgo biloba, Coenzyme Q10, and natural flavonoids blend, in which a content of the trans-resveratrol is about 250 mg; a content of the ginkgo biloba is about 120 mg; a content of the Coenzyme Q10 is about 100 mg; and a content of the natural flavonoids blend is about 256 mg. The natural flavonoids blend may include quercetin, fisetin derived from strawberries; and anthocyanidin and anthocyanin derived from European blueberry extracts. The dietary supplement composition according another aspect includes at least three of trans-resveratrol, ginkgo biloba, Coenzyme Q10, and natural flavonoids blend. The dietary supplement compositions further includes zinc gluconate, cyanocbalamin and taurine.

Abstract: Chromatin peptide drug molecules, which can block human cell hypoxia responsive pathway, are DNA affinity structural domain of related transcription genes or their imitating molecules or derivatives, containing 5-100 amino acid residues which can specifically bind firmly to HIF-1? gene self promoter or its downstream regulated more than 40 gene promoters. The above-mentioned molecules can permanently shut down molecular pathway including cell glucolysis reaction, immuno-inflammation reaction or hypoxia response, thus sustained stop uncontrollable proliferation of later stage tumor cells or chronic inflammation cells in the condition of hypoxia.

Abstract: Chromatin peptide drug molecules, which can block human cell hypoxia responsive pathway, are DNA affinity structural domain of related transcription genes or their imitating molecules or derivatives, containing 5-100 amino acid residues which can specifically bind firmly to HIF-1? gene self promoter or its downstream regulated more than 40 gene promoters. The above-mentioned molecules can permanently shut down molecular pathway including cell glucolysis reaction, immuno-inflammation reaction or hypoxia response, thus sustained stop uncontrollable proliferation of later stage tumor cells or chronic inflammation cells in the condition of hypoxia.

Abstract: This invention discloses two peptides and their derivatives that are anti-angiogenic and method for treating cancer and other diseases related to angiogenesis.

Abstract: The present invention is an isolated and purified DNA sequence which encodes a vertebrate mRNA for a neuron specific protein, neuronatin. The mRNA is selectively expressed in brain tissue during rapid brain growth when there is a surge in neuronal proliferation and migration and is repressed in adult tissue. In the human, the genomic DNA is as set forth in SEQ ID No:6 and the cDNA has a nucleotide sequence as set forth in SEQ ID No:5, with the gene mapped to human chromosome 20q11.2-12. The deduced protein is a proteolipid that appears to have a role in ion channel regulation during brain development.